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The natural function of the malaria parasite’s
chloroquine resistance transporter
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Manuel Llinás 3, Simon J. Hogg 1, Robert L. Summers1, Malcolm J. McConville 2 & Rowena E. Martin 1✉
The Plasmodium falciparum chloroquine resistance transporter (PfCRT) is a key contributor to
multidrug resistance and is also essential for the survival of the malaria parasite, yet its
natural function remains unresolved. We identify host-derived peptides of 4-11 residues,
varying in both charge and composition, as the substrates of PfCRT in vitro and in situ, and
show that PfCRT does not mediate the non-specific transport of other metabolites and/or
ions. We find that drug-resistance-conferring mutations reduce both the peptide transport
capacity and substrate range of PfCRT, explaining the impaired fitness of drug-resistant
parasites. Our results indicate that PfCRT transports peptides from the lumen of the para-
site’s digestive vacuole to the cytosol, thereby providing a source of amino acids for parasite
metabolism and preventing osmotic stress of this organelle. The resolution of PfCRT’s native
substrates will aid the development of drugs that target PfCRT and/or restore the efficacy of
existing antimalarials.
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To grow and multiply within the erythrocyte, the malariaparasite takes up the host cell cytosol into an acidic com-partment known as the digestive vacuole (DV, pH
5.0–5.51,2). The internalised host proteins, 50–80% of which are
haemoglobin3,4, are degraded by DV-localised proteases into
peptides and amino acids5. The digestion of the erythrocyte
cytosol provides space6 and amino acids7 for parasite growth and
multiplication, and helps maintain the osmotic balance of the
parasitised cell8,9. Consistent with its crucial role in the biology of
the parasite, the DV is also where many antimalarials act, accu-
mulate and/or are activated10.
The P. falciparum ‘chloroquine resistance transporter’ (PfCRT)
resides in the DV membrane and is pivotal to the normal phy-
siology of this organelle as well as to its extensive involvement in
drug resistance11–13. PfCRT was originally identified as the main
determinant of chloroquine (CQ) resistance, but mutations in this
protein are now known to modulate the parasite’s sensitivity to
many current and upcoming antimalarials14. The main
mechanism by which these mutations confer drug resistance is
through enabling the transporter to efflux a drug, such as CQ,
from the DV and thus away from its primary site of action10,15,16.
PfCRT is also essential for the survival of the parasite and has
itself been identified as a drug target17–19. For instance, potent
inhibition of mutant PfCRT results in parasite death20,21 and
downregulation of PfCRT expression causes impaired growth and
DV swelling22. Furthermore, the mutations that confer drug
resistance typically impose a fitness cost upon the parasite, the
severity of which is dependent upon the number and nature of
the mutations23–27. For example, the ‘Dd2’ isoform (PfCRTDd2)
imparts a significant fitness cost (and a high level of CQ resis-
tance), whereas the ‘Ecu1110’ isoform (PfCRTEcu1110) imposes a
smaller fitness disadvantage but also confers a lower level of CQ
resistance. Moreover, two PfCRT mutations that arose separately
under in vitro drug pressure (C101F and L272F) incur both a
fitness cost and a monstrously swollen DV13.
Although these findings indicate that PfCRT is crucial for
parasite growth and replication, and for maintaining the osmotic
homoeostasis of the DV, its native substrates and function remain
unresolved. Attempts to characterise PfCRT in heterologous
expression systems have produced wildly disparate results, with it
being claimed to function as either a Cl− channel28,29, a H+
pump30, a non-specific cation channel31, an activator of H+
pumps and of non-specific cation channels31, a glutathione
transporter32, a non-specific transporter of inorganic and organic
cations as well as of many other metabolites33, or an Fe2+/Fe3+
transporter34. Moreover, none of these studies undertook
experiments with parasites to substantiate that PfCRT exhibited
the proposed transport activity in situ and that mediating this
activity was the protein’s physiological role.
Here, we use the Xenopus oocyte expression system in con-
junction with measurements of solute transport, drug activity and
metabolite levels in transgenic parasite lines to provide a detailed
elucidation of the native substrate-specificity and physiological
role of PfCRT. We show that PfCRT functions to export host-
derived peptides 4–11 residues in length from the parasite’s DV,
and that the protein does not behave as a non-specific transporter
of other metabolites and/or ions. The transport of peptides and
peptide mimics via PfCRT is saturable, blocked by known PfCRT
inhibitors, and is dependent on protons as well as on a co-
substrate that remains to be identified. Relative to the wild-type
protein, the drug-resistance-conferring isoforms of PfCRT
recognise far fewer peptides and peptide mimics, and have
markedly lower maximum rates of peptide transport. The
reduced capacities of mutant PfCRT isoforms for transporting
peptides out of the DV results in the accumulation of the sub-
strate peptides in drug-resistant parasite lines. Together, our
findings provide a molecular basis for why PfCRT is essential for
parasite survival and why drug-resistance-conferring mutations
in the transporter impart a fitness cost. We present a mechanistic
model in which the PfCRT-mediated transport of peptides from
the DV to the cytosol serves to (1) provide a source of amino
acids to support the parasite’s high growth rate and (2) reduce
peptide levels within the DV and thereby prevent the osmotic
stress, swelling and dysfunction of this organelle.
Results
Cis-inhibition screens identify putative substrates of PfCRT. A
large collection of metabolites and ions was screened for mole-
cules that interact with the substrate-binding cavity of PfCRT in
the Xenopus oocyte system15. Our approach utilised two CQ-
resistance-conferring isoforms of PfCRT (PfCRTEcu1110 and
PfCRTDd2) which, unlike wild-type PfCRT (PfCRT3D7), transport
tritiated CQ ([3H]CQ) into the oocyte16. This property was
exploited to detect unlabelled solutes that inhibit [3H]CQ uptake,
consistent with them interacting with the mutant transporter’s
substrate-binding cavity (Fig. 1a).
None of the test solutes affected the accumulation of [3H]CQ
in the negative controls, and most solutes also failed to cis-inhibit
[3H]CQ transport via PfCRTEcu1110 or PfCRTDd2 (Fig. 1b–d;
Supplementary Data 1, 2 and Supplementary Note 1). By
contrast, almost all of the 95 peptides screened strongly cis-
inhibited [3H]CQ transport by both PfCRTEcu1110 and
PfCRTDd2. The test peptides were 2–25 residues in length and
most occur in haemoglobin or other erythrocyte proteins. Only
the dipeptides LH and GQ were without effect. Two
haemoglobin-derived peptides, VDPVNF (VF-6) and HVDDM
(HM-5), were selected for further characterisation and were
confirmed to cis-inhibit [3H]CQ transport via PfCRTDd2 in a
concentration-dependent manner (Fig. 1e).
Peptides containing 4–11 residues trans-stimulate PfCRT. The
cis-inhibition assay identifies compounds that interact with
PfCRT, but does not distinguish between solutes that inhibit (and
are not translocated) and those that are substrates of PfCRT. We
therefore employed a trans-stimulation assay to investigate
whether the host-derived peptides are substrates of PfCRT
(Fig. 2a). Trans-stimulation is a phenomenon exhibited by many
carrier-type transporters (such as PfCRT21,35) whereby the
reorientation of the binding site between the two faces of the
membrane occurs more rapidly when it is occupied by a substrate
than when it is empty (Supplementary Note 2). This property
means that the PfCRT-mediated uptake of [3H]CQ from the
extracellular solution will increase when an unlabelled substrate is
present on the cytosolic face of the membrane, but will be
unaffected by the presence of solutes that do not interact with the
transporter21.
None of the test solutes affected [3H]CQ accumulation in the
negative controls, and LH was without effect in all oocyte types
(Fig. 2b–g; Supplementary Fig. 1 and Supplementary Data 1, 2).
Moreover, the solutes that had failed to cis-inhibit PfCRT also did
not trans-stimulate [3H]CQ uptake, confirming that they are not
substrates of the transporter (Fig. 2b, c, g; Supplementary Note 2, 3).
By contrast, of the 93 peptides found to cis-inhibit PfCRT, 32 trans-
stimulated [3H]CQ transport via PfCRTEcu1110 and 23 of these
peptides also trans-stimulated PfCRTDd2. Somewhat unexpectedly,
39 peptides trans-stimulated [3H]CQ transport via PfCRT3D7. This
finding revealed that although CQ transport via PfCRT3D7 cannot
be detected under normal conditions in the oocyte system or
in situ36,37, the wild-type transporter can mediate a low level of CQ
transport when trans-stimulated by high concentrations of a
peptide substrate. The trans-stimulation of PfCRT3D7 by VF-6
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was pH-dependent, but was unaffected by the removal of Na+ from
the injection buffer (Fig. 2d, e).
The potent trans-stimulatory effects of VF-6 and HM-5 were
concentration-dependent (Fig. 2f). In both cases, the Michaelis
constant (Km) values increased in the order PfCRT3D7 <
PfCRTEcu1110 < PfCRTDd2 and the maximal velocities (Vmax)
decreased in the order PfCRT3D7 > PfCRTEcu1110 > PfCRTDd2.
That is, PfCRT3D7 was trans-stimulated at lower peptide
concentrations and to a greater extent than the mutant
transporters.
The trans-stimulation of [3H]CQ transport by VF-6 was not
due to its breakdown into small fragments, as the injection of
amino acids, dipeptides or tripeptides derived from VF-6 failed to
trans-stimulate PfCRT. By contrast, all of the VF-6-derived
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peptides containing ≥4 residues trans-stimulated [3H]CQ trans-
port (Supplementary Fig. 1 and Supplementary Data 1, 2).
The antiretroviral drug saquinavir has previously been shown
to interact with PfCRTDd238. We therefore tested a number of
peptide mimics and found that several—including saquinavir—
cis-inhibited and trans-stimulated [3H]CQ transport via
PfCRT3D7, PfCRTEcu1110 and PfCRTDd2 (Fig. 2b, c; Supplemen-
tary Fig. 1 and Supplementary Data 1, 2).
Collectively, these findings indicate that PfCRT transports a
broad range of peptides that contain 4–11 amino acid residues,
are neutral, negatively or positively charged at pH 5.5 (with a bias
towards a net negative charge), and do not have a particular
sequence (Supplementary Fig. 1). Furthermore, PfCRT3D7 accepts
a broader range of peptides than either PfCRTEcu1110 or
PfCRTDd2; [3H]CQ transport via PfCRT3D7 was trans-stimulated
by 46 peptides and peptide mimics, which is 9 more than
PfCRTEcu1110, and 20 more than PfCRTDd2.
Characterisation of peptide transport via PfCRT. We sought to
obtain a direct demonstration of peptide transport via PfCRT by
undertaking radioisotope transport assays with one of the potent
trans-stimulators of all three PfCRT isoforms. A tritiated analo-
gue of VF-6 was obtained and numerous unsuccessful attempts
were made to measure its uptake from the extracellular solution
into oocytes expressing PfCRT3D7, PfCRTEcu1110 or PfCRTDd2.
However, when [3H]VF-6 was injected into the oocyte, all three
PfCRT isoforms mediated its efflux from the oocyte, whereas [3H]
VF-6 transport was not detected in the negative controls
(Fig. 3a–e). This assay was therefore employed to characterise
peptide transport via PfCRT. The efflux of [3H]VF-6 from
PfCRT-expressing oocytes was linear over time for at least 2 h and
was dependent on both the pH of the injection buffer and the
oocyte membrane potential (see also Supplementary Fig. 2 and
Supplementary Note 4). By contrast, removal of Na+ or Cl− from
the injection buffer, or varying the Ca2+ concentration, was
without effect (Supplementary Fig. 2). VF-6 transport via all three
PfCRT isoforms was saturable, with PfCRT3D7 having a slightly
lower affinity, but much higher capacity, for VF-6 transport
relative to the two mutant transporters.
Several drugs known to interact with the substrate-binding
cavity of PfCRT were found to inhibit [3H]VF-6 transport via
the three PfCRT isoforms (Fig. 3f–i; Supplementary Fig. 3). These
were verapamil15,39 and chlorpheniramine40 (both partial
reversers of CQ resistance in vitro), the quinine dimer ‘Q2C’
(currently the most potent inhibitor of PfCRTDd2)20, CQ15
and saquinavir38. Q2C was the most potent cis-inhibitor, with
half-maximum inhibitory concentrations (IC50) in the nano-
molar range. With the exception of saquinavir, the drug IC50s
decreased in the order PfCRT3D7 > PfCRTEcu1110 > PfCRTDd2,
and similar IC50s and trends were obtained when verapamil,
chlorpheniramine, CQ and Q2C were tested for the ability to
trans-inhibit [3H]VF-6 transport via PfCRT. By contrast, the
saquinavir cis-inhibition IC50s increased in the order PfCRT3D7 <
PfCRTEcu1110 < PfCRTDd2. Moreover, saquinavir trans-stimu-
lated [3H]VF-6 transport via all three PfCRT isoforms. Given
this result, and the fact that [3H]CQ is readily taken up into the
oocyte from the extracellular solution via PfCRTDd2 and
PfCRTEcu1110, we explored whether high extracellular concentra-
tions of CQ would trans-stimulate, rather than trans-inhibit, the
efflux of [3H]VF-6. We observed modest trans-stimulation of
[3H]VF-6 transport via all three PfCRT isoforms when [CQ] ≥
500 μM.
These findings led us to test whether a subset of the host-
peptides that trans-stimulated CQ transport via PfCRT were
likewise able to trans-stimulate [3H]VF-6 transport. However, all
of the test peptides (including unlabelled VF-6) trans-inhibited
[3H]VF-6 transport via PfCRT, whereas the compounds included
as negative controls (LH and free amino acids) were without
effect (Fig. 3j). This result, together with the inability of PfCRT to
take up [3H]VF-6 from the external solution, indicated that a co-
substrate is required for peptide transport via PfCRT. All three
solutes—peptide, proton and the unidentified co-substrate—must
be present on the same side of the membrane for the PfCRT-
mediated transport of host-derived peptides to occur. The
requirement for a co-substrate was unexpected given that the
drugs transported by PfCRT—e.g. CQ, quinine, quinidine,
quinacrine, methylene blue and saquinavir—only require protons
to undergo translocation15,21,39,41 (see also Supplementary
Note 4). However, the decoupling of some substrates, but not
others, from the translocation of a co-substrate is a known
phenomenon in carrier-type transporters42–44. The co-substrate
is evidently present in the oocyte cytosol, but absent from the
extracellular buffer. We screened many solutes, including Fe2+,
Fe3+ and glutathione, but were unable to identify the co-substrate
(Supplementary Data 1). Moreover, re-screening of a range of
radiolabelled metabolites as potential substrates via injection into
the oocyte failed to detect transport via PfCRT (Fig. 3k), nor were
any of these radiolabelled solutes taken up via PfCRT when added
to the external solution (Supplementary Fig. 3). Yet within the
same assays, [3H]CQ and [3H]hypoxanthine were transported
(both out of and into the oocyte) via mutant PfCRT and PfNT1,
respectively (Fig. 3k; Supplementary Fig. 3i).
Diverse isoforms of PfCRT transport the VF-6 peptide. A
broad range of PfCRT isoforms were expressed in the oocyte
system (Supplementary Fig. 4). All of the field PfCRT isoforms
transported VF-6, albeit to varying degrees (Fig. 4a; the positions
of the mutations in PfCRT are shown in Supplementary Fig. 5).
The kinetics of VF-6 transport via several of these proteins were
indistinguishable from those of PfCRT3D7 (e.g., the 2300, 106/1,
Fig. 1 Screening of a solute library for cis-inhibitory activity identified potential substrates of PfCRT. a Schematic showing the cis-inhibition of [3H]CQ
uptake via PfCRTDd2 or PfCRTEcu1110 by an unlabelled solute in the Xenopus oocyte system. The library included solutes known to exist in the parasitised
erythrocyte, such as vitamins, carbohydrates, metal ions, lipids, amino acids, peptides and other organic and inorganic molecules. b, c The effect on [3H]CQ
transport via PfCRT by a subset of solutes (2 mM) (b) or host-derived peptides (2 mM) (c). Non-expressing oocytes and those expressing PfCRT3D7 were
included as negative controls; these oocytes accumulate a low level of [3H]CQ via simple diffusion of the neutral species15,16, reflecting the background
level of [3H]CQ transport. Note that aspartate and vitamins E and B6 caused modest reductions in PfCRTDd2-mediated transport, but only aspartate was
found to inhibit PfCRTEcu1110. A diverse range of peptides cause potent inhibition of both PfCRTDd2 or PfCRTEcu1110. d Heatmap of the cis-inhibition of [3H]
CQ transport via PfCRTDd2 and PfCRTEcu1110 by 173 different solutes. e VF-6 (top) and HM-5 (bottom) inhibit [3H]CQ transport via PfCRTDd2 in a
concentration-dependent manner. The half-maximum inhibitory concentrations (IC50) for VF-6 and HM-5 are 207 ± 12 and 167 ± 14 µM, respectively. The
data are the mean of n= 4 independent experiments (each yielding similar results and overlaid as individual data points in b and c), and the error is the
SEM. Where not visible, the error bars fall within the symbols. The asterisks denote a significant difference from the relevant PfCRTDd2 (red asterisks) or
PfCRTEcu1110 (orange asterisks) control; *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA). The source datasets are provided as a Source Data file.
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BC22 and Cam738 isoforms), whereas almost all of the CQ-
resistance-conferring isoforms displayed significantly lower
capacities for VF-6 transport (e.g., the China e, GB4, 783 and K1
isoforms). Moreover, field isoforms that arose from the intro-
duction of a positively charged residue into a CQ-resistance-
conferring variant of PfCRT showed a marked increase in VF-6
transport activity relative to their respective parent isoforms, but
had lost the ability to transport CQ (e.g., cf. PfCRTK1 with
PfCRT106/1 and PfCRT2300; Fig. 4a, Supplementary Fig. 6). These
findings confirm the importance of electrostatic charges at key
positions within PfCRT in determining the transporter’s
substrate-specificity16,21. They also provide a mechanistic
explanation for why the re-introduction of a positively charged
residue into PfCRT’s binding cavity re-sensitises the parasite to
CQ while simultaneously restoring its innate fitness23,45.
The relationship between the CQ and VF-6 transport activities
of field PfCRT isoforms was examined to gain further insights
into the correlation between mutations in PfCRT and reduced
parasite fitness. The VF-6 transport activity of PfCRT decayed
exponentially as its capacity to transport CQ increased (Fig. 4b;
Supplementary Fig. 6). That is, a given reduction in peptide
transport activity imparts a larger increase in CQ transport
activity. A significant outlier to this relationship was
PfCRTCam734; its capacity for VF-6 transport exceeded that of
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PfCRT3D7, but it also possessed a moderate level of CQ transport
activity. This finding is consistent with the observation that
parasites expressing PfCRTCam734 do not display a fitness
disadvantage relative to wild-type parasites, and yet are
moderately resistant to CQ46.
Three laboratory-derived isoforms that cause a gross enlarge-
ment of the DV13—L272F-PfCRT3D7, L272F-PfCRTDd2 and
C101F-PfCRTDd2—displayed unusually low capacities for VF-6
transport (Fig. 4a). This observation provides a molecular basis
for understanding why PfCRT is critical for maintaining the
normal osmotic pressure and morphology of the DV.
We found that the fusion of polypeptides to the N- or C-
termini of PfCRT interfere with its natural function. Although
only one of the modified PfCRTDd2 proteins no longer mediates
[3H]CQ transport (Fig. 4c, left panel), all of the tagged versions of
PfCRT3D7 and PfCRTDd2 have lost the ability to transport [3H]
VF-6 (Fig. 4c, right panel). This observation helps to explain why
previous studies, which expressed versions of PfCRT with N-
and/or C-terminal fusions, did not delineate the native substrates
of PfCRT (Supplementary Note 5).
Peptide mimics are substrates of PfCRT in situ. We sought to
verify that PfCRT also functions as a peptide transporter within
its native environment of the DV membrane. PfCRT activity was
measured using the in situ ‘H+-efflux assay’ (Fig. 5a) with a set of
P. falciparum transfectants that are isogenic except for their pfcrt
allele. These lines, known as C2GC03, C67G8 and C4Dd2, express
either PfCRT3D7, PfCRT7G8 (which harbours the mutations
present in PfCRTEcu1110 plus C72S) or PfCRTDd2, respectively47.
The weak-base solute under study enters the parasite’s acidic DV
via simple diffusion of the neutral species, and/or via transporters
such as the multidrug resistance protein 1 (PfMDR148,49), and
becomes protonated (Fig. 5a). Peptide mimics and modified host-
peptides (Supplementary Fig. 6) were used in these assays due to
their increased membrane permeability, and resistance to pro-
teolytic degradation, relative to natural peptides.
Histidine, ritonavir and lopinavir were without effect in all of
the lines, indicating that either they are not substrates of PfCRT,
or that insufficient levels of these solutes accumulate within, and
are effluxed from, the DV to induce a detectable H+ leak. By
contrast, several peptides and peptide mimics induced a H+ leak
in one or more of the parasite lines, consistent with them being
substrates of PfCRT. Saquinavir and two modified host-peptides
(Ac-YF-5-NH2 and Ac-ST-7-NH2; Supplementary Fig. 7)
increased the rate of DV alkalinisation in all three lines, with
the effect decreasing in the order C2GC03 > C67G8 > C4Dd2.
Moreover, leupeptin and E-64 both caused a H+ leak in
C2GC03 parasites, and leupeptin also induced a H+ leak in the
C67G8 line, but neither peptide exerted an effect in C4Dd2. That is,
as was observed in the oocyte system, the range of peptides
transported decreases in the order PfCRT3D7 > PfCRT7G8 >
PfCRTDd2.
Verapamil and Q2C inhibited the peptide-induced H+ leaks in
C2GC03, C67G8 and C4Dd2 parasites (Fig. 5b), providing further
evidence that the peptide mimics and modified peptides are
exported from the DV via PfCRT. Moreover, as observed in the
oocyte system, Q2C was the most potent inhibitor, and both Q2C
and verapamil were more effective against the mutant transpor-
ters than against PfCRT3D7.
Kinetic analyses revealed that the peptides increase the rate of
DV alkalinisation in a concentration-dependent manner (Fig. 5c;
Supplementary Fig. 8), with the capacity for transport decreasing
in the order PfCRT3D7 > PfCRT7G8 > PfCRTDd2. The same trend
was observed in the oocyte system when we measured the
concentration-dependence of the trans-stimulation of [3H]CQ
transport via PfCRT by these peptides (Fig. 5d; Supplementary
Fig. 8), again confirming the strong consensus in the transport
properties of PfCRT between the two experimental systems.
The finding that the mutant transporters have reduced
capacities for exporting saquinavir suggested that this peptide
mimic may be better retained within the DV of CQ-resistant
parasites and could thereby affect their sensitivity to this protease
inhibitor (which is suspected to exert its weak antimalarial
activity inside the DV). We therefore determined the IC50 of
saquinavir against the three isogenic lines as well as to CQ-
sensitive (3D7) and CQ-resistant (7G8 and Dd2) strains (Fig. 6,
see Supplementary Fig. 8 for parasite susceptibilities to other
peptide mimics). As expected, the parasites expressing mutant
PfCRT isoforms were more susceptible to saquinavir than those
expressing PfCRT3D7. Moreover, verapamil was shown to
increase parasite sensitivity to saquinavir.
Together, these datasets provide a robust demonstration of
peptide transport via PfCRT in situ. They also indicated that the
reduced capacity of the mutant transporters for exporting host-
derived peptides would cause these catabolites to accumulate
within the DV.
Parasites with mutant isoforms of PfCRT accumulate peptides.
Two previous metabolomic analyses have reported that CQ-
resistant parasites accumulate significantly more aspartate and
peptides than their CQ-sensitive counterparts27,50. However, it
was unclear how to reconcile these metabolite profiles with (1) the
inability of PfCRT to translocate amino acids and small peptides
and (2) our identification of host-peptide substrates of PfCRT
that were not detected, or were reported as non-significant, in
these studies. We therefore undertook quantitative peptidomic
Fig. 2 PfCRT is trans-stimulated by peptides containing 4–11 amino acid residues. a Schematic showing the trans-stimulation of [3H]CQ transport via
PfCRT by an unlabelled substrate in Xenopus oocytes. b, c Trans-stimulation of [3H]CQ transport via PfCRTDd2 or PfCRTEcu1110 (b) or via PfCRT3D7 (c) by a
subset of host-derived peptides and peptide mimics (45mM). The test solute was injected into the oocyte immediately prior to the commencement of the
assay, with the buffer-only and LH treatments serving as injection controls21. The negative controls were non-expressing oocytes and those expressing
an unrelated P. falciparum transporter, the nucleoside transporter 1 (PfNT175,76). The latter demonstrates that the expression of a similarly sized transporter
in Xenopus oocytes does not affect the ability of the oocyte membrane to reseal following injection of a test solute21. d Trans-stimulation of [3H]CQ
transport via PfCRT3D7 by VF-6 (45mM) is pH-dependent, with the largest increase observed when the pH of the injection buffer was 5.5 (equating to
79 fmoles H+). e Trans-stimulation of [3H]CQ transport via PfCRT is unaffected by the removal of Na+ from the injection buffer. f Concentration-
dependence of the trans-stimulation of [3H]CQ transport via PfCRT by VF-6 (left) and HM-5 (right). The non-expressing oocyte data overlays the data
obtained with oocytes expressing PfNT1. g Heatmap of the trans-stimulation of [3H]CQ transport via PfCRT3D7, PfCRTEcu1110 or PfCRTDd2 by 173 different
solutes. Only peptides and peptide mimics trans-stimulate PfCRT; all other solutes, including aspartate and vitamins E and B6, failed to increase [3H]CQ
transport via PfCRT are thus unlikely to be substrates of the transporter. The data are the mean of n= 4 independent experiments (each yielding similar
results and overlaid as individual data points in b, c and e), and the error is the SEM. Where not visible, the error bars fall within the symbols. The asterisks
denote a significant difference from the relevant PfCRTDd2 (red asterisks), PfCRTEcu1110 (orange asterisks) or PfCRT3D7 (blue asterisks) buffer-injected
control; *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant (one-way ANOVA). SQV: saquinavir. The source datasets are provided as a Source Data file.
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analyses to examine the populations of host-derived peptides
present in the C2GC03, C67G8 and C4Dd2 parasites (Supplemen-
tary Data 3–5). Peptides of varying length, composition and
charge were detected, with most originating from haemoglobin
and the remainder from other erythrocytic proteins. Several of
these peptides accumulated to high levels within the CQ-resistant
parasites relative to the C2GC03 line (Supplementary Data 3–5),
including VF-6 and other peptides we had designated from the
trans-stimulation assays as likely substrates of PfCRT.
The apparent agreement between the trans-stimulation and
peptidomic datasets for the initial set of peptides studied in the
oocyte system led us to test the potential of the accumulation
profiles to predict whether a given peptide was a substrate of
PfCRT. These predictions also considered the length of the
trans-stimulation
[VF-6] (μM)
µ
[Q2C] (μM)
[VP] (μM)
cis-inhibition
cis-inhibition
trans-inhibition Fragments of VF-6
H+ injected (fmol)Time (min)
0
24
18
12
6
0
0 400 800 1200
0 0 50 100 150 200 25030 60 90 120
30
60
90
[3 H
]V
F-
6 t
ran
sp
ort
(%
 P
fC
RT
3D
7  
a
t 9
0 
m
in
)
[3 H
]V
F-
6 t
ran
sp
ort
(%
 P
fC
RT
3D
7  
a
t 7
9 
fm
ol
 H
+
)
120
0
30
60
90
[3 H
]V
F-
6 t
ran
sp
ort
(%
 P
fC
RT
3D
7  
co
n
tro
l)
Pf
CR
T-
m
ed
ia
te
d
VF
-6
 tr
an
sp
or
t
(pm
ol/
oo
cy
te/
h)
120
0
25
50
75
100
[3 H
]V
F-
6 t
ran
sp
ort
(%
 P
fC
RT
3D
7  
co
n
tro
l)
0
0 10 20 30 40 50
25
50
75
100
[3 H
]V
F-
6 t
ran
sp
ort
(%
 P
fC
RT
3D
7  
co
n
tro
l)
[3 H
]V
F-
6 t
ran
sp
ort
(%
 P
fC
RT
3D
7  
co
n
tro
l)
0
0 2 4 6 8 10
25
50
75
100
[3 H
]V
F-
6 t
ran
sp
ort
(%
 P
fC
RT
3D
7  
co
n
tro
l)
0
Co
ntr
ol
[3 H
]L-a
lan
ine
[3 H
]L-a
rgin
ine
[3 H
]L-a
spa
rtic
 ac
id
[3 H
]L-g
luta
mic
 ac
id
[3 H
]L-l
ysin
e
[3 H
]L-a
cet
ate
[3 H
]L-f
ola
te
[3 H
]L-f
orm
ate
[3 H
]L-l
act
ate
[3 H
]L-s
per
mid
ine
[3 H
]L-t
hym
ine
[3 H
]CQ
[3 H
]hy
pox
ant
hin
e
LH VD PV
N
DP
VN
DP
VN
F
VF
-6
PV
NF
VD
PV
N
V, 
D, 
P, 
V, 
N, 
F
25
50
75
100
Tr
an
sp
or
t o
f [3
H
]co
mp
ou
nd
(%
 no
n-e
xp
res
sin
g o
oc
yte
s)
0
25
50
75
100
3000
2000
1000
Tr
an
sp
or
t o
f [3
H
]co
mp
ou
nd
(%
 no
n-e
xp
res
sin
g o
oc
yte
s)
0
[SQV] (μM)
0 10 20 30 40 50
0
50
100
150
Membrane potential (mV)
–80 –60 –40 –20 0 20 40 60 80
pH 5.5a
d
g
i
k
h
j
e f
b c
[3H]VF-6
CRT
Direct measurement
of [3H]VF-6 transport
pH ~7.1
Drug
Cis-inhibition IC50s (μM)
PfCRT3D7 PfCRTEcu1110 PfCRTDd2
VP 17.5 ± 1.1 9.5 ± 1.9* (0.5) 6.8 ± 1.8** (0.4)
CP 9.8 ± 0.5 6.2 ± 0.3* (0.6) 5.0 ± 1.1** (0.5)
CQ 110 ± 5.9 72 ± 3.1** (0.7) 53 ± 2.8*** (0.5)
Q2C 0.6 ± 0.02 0.08 ± 0.007*** (0.1) 0.01 ± 0.002*** (0.02)
SQV 50 ± 2.3 74 ± 3.9** (1.5) 89 ± 3.8*** (1.78)
Non-expressing
oocytes
PfCRT3D7
PfCRTEcu1110
PfCRTDd2
PfNT1
Legend:
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17781-6 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3922 | https://doi.org/10.1038/s41467-020-17781-6 | www.nature.com/naturecommunications 7
peptides (i.e. 4–11 residues) transported by PfCRT. Of the 41
peptides selected for a second round of testing, 22 were predicted
to be substrates, 14 were predicted not to be substrates and 5
could not be confidently assigned a prediction from the
peptidomic data. All 22 of the predicted substrates trans-
stimulated [3H]CQ transport via PfCRT and all 14 of the
predicted non-substrates were without effect. Of the 5 unassigned
peptides, one was found to be a PfCRT substrate and the other
four failed to trans-stimulate the transporter. We also showed
that several of the non-haemoglobin erythrocytic peptides
detected in the peptidomic analyses are substrates of PfCRT
(Supplementary Data 1 and 2).
Overall, there is a strong positive relationship between the
accumulation within CQ-resistant parasites of peptides 4–11
residues in length and their capacity to trans-stimulate PfCRT
(Fig. 7). Two types of exceptions to this correlation are outlined in
Supplementary Note 6. These caveats aside, our findings indicate
that the peptidomic datasets can be employed to infer which host-
derived peptides are likely to be substrates of PfCRT.
The CQ-resistant lines tended to contain lower levels of the
large host-derived oligopeptides (>15 residues) relative to the
shorter fragments within a given degradation cascade. This is
consistent with the digestive process (and thus parasite growth)
being slowed down in CQ-resistant parasites in response to an
over-accumulation of PfCRT’s peptide substrates within the DV.
Discussion
Our work has provided a definitive resolution of the natural
substrates and physiological role of PfCRT, a key contributor to
multidrug resistance in the malaria parasite. Contrary to previous
reports, PfCRT is not a non-specific transporter of metabolites
and/or of organic or inorganic ions. Instead, the datasets we have
obtained using a set of complementary in vitro and in situ assays
reveal that PfCRT exports host-derived peptides containing 4–11
residues out of the parasite’s DV. Peptide transport via PfCRT
shows a slight bias towards negatively charged peptides, is
saturable at micromolar concentrations, and is blocked by known
PfCRT inhibitors, including verapamil, chlorpheniramine and
Q2C. Moreover, the transport of peptides is dependent on protons
as well as on a second solute that remains to be identified, but
which is naturally present in the Xenopus oocyte. We found that
most resistance-conferring isoforms of PfCRT, which efflux CQ
from the DV but also typically impart a fitness cost to the
parasite, exhibit reduced rates of peptide transport. Furthermore,
relative to wild-type PfCRT, the mutant transporters accept a
narrower range of peptide substrates.
The significant reductions in the capacities of the mutant
proteins to efflux peptides from the DV account for the elevated
levels of peptides we measured within CQ-resistant parasites.
Moreover, the relative capacities of different PfCRT isoforms to
mediate peptide transport can be readily reconciled with the
magnitude of the phenotypes displayed by the corresponding
parasites. For example, peptide transport activity decreases in the
order PfCRT3D7 > PfCRT7G8 > PfCRTDd2 and this mirrors
the degree to which peptides of 4–11 residues accumulate within
the respective parasite lines (C2GC03 < C67G8 < C4Dd2) as well
as the extent of the fitness costs imparted by the mutant trans-
porters51. Likewise, a poor capacity for peptide transport corre-
lates with increased osmotic stress (i.e. swollen DVs). That is, the
L272F and C101F variants of PfCRT have very low peptide
transport activities and cause grossly enlarged DVs, and parasites
carrying PfCRTDd2, which has one of the poorest capacities for
peptide transport amongst the field isoforms of the protein, dis-
play moderately swollen DVs.
Our quantitative peptidomic analyses of the C2GC03, C67G8
and C4Dd2 lines, together with previous metabolomic studies of
these parasites27,50, point to further metabolic manifestations of
the reduced capabilities of mutant isoforms for peptide transport.
First, the peptide substrates accumulating within the DV of CQ-
resistant parasites appear to be promiscuously degraded into
smaller peptides and amino acids. The generation of these cata-
bolites would add significantly to the osmotic stress of the DV,
and this could explain why polymorphisms in a putative amino
acid transporter (PfAAT1), a resident of the DV membrane, have
been linked to resistance to CQ and other compounds14,52. The
changes to PfAAT1 likely increase its capacity for exporting
amino acids and/or small peptides from the DV. Secondly, the
build-up of peptides and amino acids within the DV of CQ-
resistant parasites appear to exert feedback inhibition upon the
degradation of host polypeptides, resulting in an accumulation of
large oligopeptides relative to the CQ-sensitive line. All of the
above perturbations to DV morphology and metabolism, along
with our finding that the PfCRT isoforms responsible have sig-
nificantly reduced capacities for exporting host-derived peptides
from this organelle, provide the long-awaited molecular expla-
nations for how CQ-resistance-conferring mutations in PfCRT
decrease parasite fitness and why the transporter is essential for
parasite survival. Together, our findings indicate that peptide
transport via PfCRT serves two roles in the physiology of the
intraerythrocytic parasite (Fig. 8). First, the delivery of host-
derived peptides to the cytosol provides a source of amino acids
to support the parasite’s high rates of growth and multiplication.
Secondly, the concomitant reduction in peptide levels within the
DV prevents the osmotic stress, swelling and dysfunction of this
organelle.
The ongoing emergence and spread of new PfCRT isoforms
(e.g. in piperaquine-resistant isolates in Cambodia53,54) indicates
that the transporter is still evolving in response to drug pressure.
Fig. 3 Characterisation of the transport of a host-derived hexapeptide via PfCRT. a Schematic showing the transport of [3H]VF-6 via PfCRT in Xenopus
oocytes. b–e [3H]VF-6 transport via PfCRT is approximately linear with time for at least 2 h (b), is dependent on both the pH of the injection buffer (the
highest level of transport occurred at pH 5.5, equating to 79 fmoles H+) (c) and the membrane potential (with the rate of VF-6 efflux steadily decreasing as
the membrane potential became more positive) (d), and is saturable (PfCRT3D7 possesses a slightly lower affinity and higher Vmax relative to the mutant
transporters) (e). [3H]CQ influx is also dependent on the membrane potential (Supplementary Fig. 2g and Supplementary Note 3). f, g Cis-inhibition of
[3H]VF-6 transport via PfCRT by verapamil (VP) (f) and Q2C (g). h The half-maximum inhibitory concentrations (IC50s) for the cis-inhibition of [3H]VF-6
transport via PfCRT by drugs known to interact with the transporter. i Trans-stimulation of [3H]VF-6 transport via PfCRT by saquinavir (SQV). j Trans-
inhibition of [3H]VF-6 transport via PfCRT by haemoglobin-peptides (45mM). k Left: various other radiolabelled solutes are not transported out of the
oocyte by PfCRT. Right: in the same assay, [3H]CQ is effluxed via PfCRTEcu1110 and PfCRTDd2 and [3H]hypoxanthine is effluxed by PfNT1. The data are the
mean of n= 5 independent experiments (each yielding similar results and overlaid as individual data points in j and k), and the error is the SEM. Where not
visible, the error bars fall within the symbols. The non-expressing oocyte data overlays the data obtained with oocytes expressing PfNT1 in b, c, e–g and i.
The asterisks denote a significant difference from the relevant PfCRTDd2 (red asterisks), PfCRTEcu1110 (orange asterisks), PfCRT3D7 (blue asterisks) or
non-expressing (black asterisks) control; *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant (one-way ANOVA). The source datasets are provided as a
Source Data file.
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Fig. 4 Diverse field and laboratory-derived isoforms of PfCRT transport the VF-6 peptide. a The VF-6 transport activities, including kinetic parameters,
of various field and laboratory-derived PfCRT isoforms in Xenopus oocytes (Km, Michaelis–Menten constant; Vmax, maximum velocity). b The capacity of
PfCRT to transport VF-6 decays exponentially as the protein’s CQ transport activity increases (R2= 0.93). Exceptions to this trend include PfCRTCam734,
L272F-PfCRTDd2, L272F-PfCRT3D7 and C101F-PfCRTDd2. c [3H]CQ transport (left) and [3H]VF-6 transport (right) via epitope-tagged versions of PfCRT3D7
and PfCRTDd2. The version of PfCRTDd2 carrying a C-terminal 3xmyc tag does not mediate [3H]CQ transport. The other four variants of PfCRTDd2 retain all
or most of their CQ transport activity. By contrast, none of the tagged versions of PfCRT3D7 or PfCRTDd2 transport [3H]VF-6. The fusion of polypeptides to
PfCRT can therefore abolish its ability to transport peptides, even when the protein remains able to transport CQ. The data are the mean of n= 5
independent experiments (each yielding similar results and overlaid as individual data points in a and c), and the error is the SEM. Where not visible, the
error bars fall within the symbols. The asterisks denote a significant difference from the relevant PfCRTDd2 (red asterisks) or PfCRT3D7 (blue asterisks)
control; *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA). The source datasets are provided as a Source Data file.
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A point of concern in this regard is PfCRTCam734, as its peptide
transport capability is superior to that of the wild-type protein,
yet it has retained the ability to transport CQ. We now have
the means to evaluate both the peptide and drug transport
functions of these new isoforms and thereby gain significant
insights into the causes and constraints that are dictating the
evolution of PfCRT in different malarious regions. Moreover,
the knowledge we have gained of PfCRT’s native substrates,
of its ability to transport—and affect the antiplasmodial activity of
—peptide mimics, as well as of the inhibition of its natural
function by existing drugs, provides a foundation for the devel-
opment of strategies that combat malaria parasites by targeting
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Fig. 5 Peptide mimics are substrates of PfCRT in situ. a Left: schematic showing the H+-efflux assay. If a protonated solute is a substrate of PfCRT it will
cause a H+ leak when effluxed from the DV. Inhibition of the DV’s H+-ATPase by concanamycin A enables this H+ leak to be detected (with a pH-sensitive
probe) as an increase in the rate of DV alkalinisation. Right: several peptide mimics (10 μM) increase the rate of DV alkalinisation in C2GC03, C67G8 and
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parasites. This is consistent with previous applications of the H+-efflux assay36,37 and with the abilities of PfCRTEcu1110, PfCRT7G8 and PfCRTDd2 (but not
PfCRT3D7) to transport CQ when tested under normal conditions in the oocyte system15,16. Unless labelled ns, P < 0.05 relative to the absence of a test
solute. b Left: schematic showing the inhibition of PfCRT by verapamil (VP) or the quinine dimer Q2C in the H+-efflux assay. Right: the increase in the rate
of DV alkalinisation caused by saquinavir (SQV; 10 μM) and Ac-YF-5-NH2 (10 μM) is inhibited by VP (50 μM) and Q2C (1 μM). The statistical analyses
were performed relative to the SQV or Ac-YF-5-NH2 controls. c SQV (left) and Ac-YF-5-NH2 (right) increase the rate of DV alkalinisation in a
concentration-dependent manner. d Concentration-dependence of the trans-stimulation of [3H]CQ transport via PfCRT by SQV (left) and Ac-YF-5-NH2
(right) in Xenopus oocytes. The non-expressing oocyte data overlays the data obtained with oocytes expressing PfNT1. The data are the mean of n= 5
independent experiments (each yielding similar results and overlaid as individual data points in a and b), and the error is the SEM. Where not visible, the
error bars fall within the symbols. The asterisks denote a significant difference from the relevant C4Dd2 (red asterisks), C67G8 (orange asterisks) or C2GC03
(blue asterisks) control; *P < 0.05, **P < 0.01, ***P < 0.001, ns: non-significant (one-way ANOVA). The source datasets are provided as a Source Data file.
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both the normal and drug-resistance-conferring functions
of PfCRT.
Methods
Xenopus laevis frogs. Ethical approval of the work performed with female X. laevis
frogs was obtained from the Australian National University (ANU) Animal
Experimentation Ethics Committee (Animal Ethics Protocol Numbers R.BSB.01.10
and A2013/13) in accordance with the Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes. The frogs were purchased from Nasco
(Cat# LM00535M) and were housed in the Xenopus Frog Facility of the ANU
Research School of Biology in compliance with the relevant institutional and
Australian Government regulations.
Culture of parasitised erythrocytes. The use of human blood for this work was
approved by the ANU Human Research Ethics Committee (Human Ethics
Approval Numbers 2011/266 and 2017/351). The asexual intraerythrocytic stages
of three P. falciparum strains and three P. falciparum pfcrt transfectant lines were
used in this study. The strains were wild-type ‘3D7’ parasites (isolated from the
Netherlands but probably of African origin55) and the CQ-resistant parasites ‘Dd2’
(isolated from Southeast Asia) and ‘7G8’ (isolated from Brazil). The three pfcrt
transfectant lines, generated by Sidhu et al.47, were C2GC03 (a recombinant control
that retains the wild-type pfcrt allele, PfCRT3D7) and the CQ-resistant lines C67G8
and C4Dd2 (in which the wild-type pfcrt allele of the ‘GC03’ line has been replaced
with the allele from the 7G8 or Dd2 strain, respectively47). A PCR error in the
generation of the C67G8 line introduced an additional mutation (I351M) which is
not normally found in the pfcrt allele of 7G8 parasites56. The parasite cultures were
maintained at 4% haematocrit and synchronised with 5% (w/v) sorbitol57. The pfcrt
transfectant lines were maintained in the presence of the selection agents blas-
ticidin (5 μM; Sigma-Aldrich) and WR99210 (5 nM; Jacobus Pharmaceuticals).
These selection agents were not present during the experiments.
Two cell line authentication methods were used to verify the identities of the six
strains and lines used in this study. The first evaluated the CQ-resistance
phenotype of each parasite culture by performing cell proliferation assays, thereby
yielding CQ IC50s for each parasite type. The results were verified by comparing
them to previously published data21,36,37 (see the P. falciparum proliferation assay
section below for details). Mycoplasma detection assays were also performed
periodically on each of the six parasite cultures using PCR in conjunction with a
primer mix that amplifies ribosomal DNA from different mycoplasma strains58.
No mycoplasma infections were detected in any of the parasite cultures throughout
the course of this study.
PfCRT coding sequences and cRNA synthesis. The coding sequences of each
of the PfCRT isoforms were generated via site-directed mutagenesis16 using the
primers listed in Supplementary Data 6. The DNA template was a codon-
harmonised sequence of PfCRT that had been inserted into the pGEM-He-Juel
oocyte expression vector59. This sequence encodes a version of PfCRT that is
free of endosomal–lysosomal trafficking motifs and thus results in the expres-
sion of the transporter at the plasma membrane of Xenopus oocytes15,16. The
plasmids were linearised with SalI (ThermoFisher Scientific) from which 5′-
capped complementary RNA (cRNA) was synthesised using the mMessage
mMachine T7 transcription kit (Ambion), and then purified with the MEGAclear
kit (Ambion).
Isolation and injection of Xenopus oocytes. Adult female frogs were anaes-
thetised in a solution of ethyl 3-aminobenzoate methanesulfonate salt (Sigma-
Aldrich) and 1 mM NaHCO3 (Sigma-Aldrich)41. Sections of the ovary were
removed and the collagenous membrane encasing the oocytes was degraded by
collagenase A and collagenase D (Sigma-Aldrich)41. Stage V–VI oocytes were
microinjected with cRNA (20 ng per oocyte) encoding a PfCRT isoform or PfNT1,
and were stored at 16–18 °C in OR2+ buffer supplemented with 50 μg/mL peni-
cillin and streptomycin.
Transport assays using Xenopus oocytes. The orientation of PfCRT in the
parasite’s DV membrane, and also in the oocyte plasma membrane, is such that its
N- and C-termini extend into the cytosol. The oocytes were suspended in a
reaction buffer adjusted to pH 5.5 to mimic the pH of the DV lumen1,2. In this
scenario, the transport of a substrate via PfCRT from the acidic extracellular
solution into the oocyte cytosol15 is analogous to the parasite’s PfCRT-mediated
efflux of a substrate from the acidic DV and into the cytosol15. Unless specified
otherwise, this is the direction in which substrate transport was measured in the
oocyte assays.
The radiolabelled compounds were purchased from either Pharmaron ([3H]VF-
6, 23 Ci/mmol), American Radiolabelled Chemicals ([3H]CQ, 20 Ci/mmol),
PerkinElmer (e.g., [3H]L-aspartate and [3H]hypoxanthine monochloride),
Amersham Biosciences ([3H]acetate and [3H]folate) or ICN Pharmaceuticals ([3H]
thymine). All of the host-derived peptides were custom-synthesised (GenScript; see
Supplementary Data 1 and 2 for peptide sequences).
Unless specified otherwise, the transport assays were conducted over 1.5 h at
27.5 °C and the reaction buffer was ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2,
1.8 mM CaCl2, 10 mM MES and 10 mM Tris-base) at pH 5.5.
Measurements of the cis-inhibition of [3H]CQ transport via PfCRTDd2 or
PfCRTEcu1110 by a test solute (data presented in Fig. 1 and Supplementary
Data 1,2) were performed on oocytes three days post-cRNA-injection15,21. Ten
oocytes were washed twice with the relevant ND96 buffer. The assay commenced
with the addition of ND96 buffer supplemented with 0.25 μM [3H]CQ, 15 μM
unlabelled CQ, and the unlabelled solute under study (at a concentration specified
in the figure legends and Supplementary Data 1, 2). The assay was terminated by
removing the reaction buffer and washing the oocytes with ice-cold ND96 buffer.
The oocytes were lysed in 10% (w/v) sodium dodecyl sulfate (SDS) and the
radioactivity accumulated within each oocyte was measured with a MicroBeta2
microplate liquid scintillation analyser (PerkinElmer).
The IC50 values presented in Fig. 1e were determined in SigmaPlot Windows
Version 11.0 by a least-squares fit of the equation y= ymin+ [(ymax− ymin)/(1+
([test compound]/IC50)c]) to the data, where y is PfCRT-mediated CQ transport,
ymin and ymax are the minimum and maximum values of y, and c is a fitted
constant. The PfCRT-mediated CQ transport presented in Supplementary Fig. 5
was calculated by subtracting the level of [3H]CQ accumulation that was detected
in the negative control oocytes (non-expressing oocytes and oocytes expressing
PfCRT3D7) from that measured in oocytes expressing PfCRTDd2 or PfCRTEcu1110.
At least four independent experiments were performed (on different days and
using oocytes from different frogs), and within each experiment measurements
were made from ten oocytes per treatment.
Parasite
line/strain Control
CQ IC50 (nM) SQV IC50 (μM)
+ 1 μM VP Control + 1 μM VP
C2GC03 27 ± 1.6 26 ± 1.3 6.8 ± 0.4 5.1 ± 0.2**
C67G8 87 ± 2.1
149 ± 4.6
25 ± 1.1
94 ± 4.4
151 ± 4.8
25 ± 0.2*** 4.2 ± 0.4 2.3 ± 0.3**
C4Dd2 26 ± 0.1*** 3.5 ± 0.5 1.9 ± 0.1**
3D7 24 ± 0.9 7.4 ± 0.3 5.9 ± 0.6**
7G8 28 ± 1.6*** 4.7 ± 0.1 2.2 ± 0.1**
Dd2 25 ± 1.0*** 3.3 ± 0.2 2.1 ± 0.3**
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Fig. 6 CQ-resistance-conferring isoforms of PfCRT increase parasite
susceptibility to saquinavir. a The antiplasmodial activities of CQ and
saquinavir (SQV) against CQ-sensitive (C2GC03 and 3D7) and CQ-
resistant (C67G8, C4Dd2, 7G8 and Dd2) parasites in the presence or
absence of verapamil (VP). The data are the mean of n= 5 independent
experiments (each yielding similar results) and the error is the SEM. The
asterisks denote a significant difference from the relevant control (red
asterisks, C4Dd2 or Dd2 control; orange asterisks, C67G8 or 7G8 control;
blue asterisks, C2GC03 or 3D7 control); **P < 0.01, ***P < 0.001, ns: non-
significant (one-way ANOVA). The source datasets are provided as a
Source Data file. b Mechanistic model for the increased susceptibility of
CQ-resistant parasites to SQV. PfCRT3D7 (wild-type PfCRT) lacks
detectable CQ transport activity, whereas the CQ-resistance-conferring
isoforms of PfCRT (mutant PfCRT) efflux CQ from the DV. VP inhibits CQ
transport via the mutant transporters, thereby re-sensitising the CQ-
resistant parasites to this antimalarial drug. By contrast, PfCRT3D7 has a
greater capacity for transporting SQV out of the DV than do the mutant
isoforms. Moreover, it is the wild-type protein that confers reduced
sensitivity to SQV. Given that VP (1) inhibits SQV transport via both the
wild-type and mutant PfCRT transporters and (2) increases the
antiplasmodial activity of SQV in all of the parasite types, our findings
indicate that SQV acts on a target within the DV.
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The ability of an unlabelled test solute to trans-stimulate [3H]CQ transport
via PfCRT (Figs. 2, 5d; Supplementary Fig. 1 and Supplementary Data 1, 2)
was measured using oocytes two days post-cRNA-injection21. The oocytes
were injected with 25 nL of an unlabelled solute (to achieve estimated
intracellular concentrations of 5–45 mM) or a control treatment (ND96 buffer
pH 5.5 or the dipeptide LH; the estimated intracellular concentration of LH was
45 mM). The intracellular concentrations were calculated using previous
estimates of the volume of stage V–VI oocytes (~400 nL60). A subset of
experiments measured the pH-dependence of the trans-stimulatory effect of
VF-6 on [3H]CQ uptake via PfCRT. The oocytes were injected with VF-6
suspended in 25 nL ND96 buffer adjusted to pH 5.0, 5.5, 6.0 or 7.0, which
corresponded to the injection of 2.5–250 fmol of H+. The Na+-dependence of
the trans-stimulatory effect of VF-6 was assessed by injecting the oocytes with
VF-6 suspended in ND96 buffer (pH 5.5) or a Na+-free version of this buffer
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Fig. 7 The peptide substrates of PfCRT accumulate in parasites expressing mutant isoforms of the transporter. Host-derived peptides in erythrocytes
infected with C2GC03 or C4Dd2 parasites were quantified using tandem liquid-chromatography mass-spectrometry and the peptide levels within the C4Dd2
line were expressed relative to those measured in the C2GC03 parasites (Supplementary Data 3 and 5). For peptides containing 4–11 residues, a positive
relationship exists between the ability to trans-stimulate CQ transport via PfCRT3D7 and accumulation within the CQ-resistant C4Dd2 parasites. The
analysis used the PfCRT3D7 trans-stimulation dataset, rather than that generated for PfCRTDd2, because the peptides most likely to accumulate in the
C4Dd2 line will include those that are very poor substrates of (or no longer transported by) PfCRTDd2. An analysis of the data with a Bayesian Information
Criteria model identified two distinct populations. The trans-stimulation data are the mean of four independent experiments (each yielding similar results)
and the peptide accumulation data are the mean of 2–6 independent experiments (each yielding similar results). Error bars are shown for data points that
are n ≥ 3; the Y error is the SD and the X error is the SEM. The source datasets are provided as a Source Data file.
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Fig. 8 Model for the natural function and physiological role of PfCRT. PfCRT transports host-derived peptides 4–11 residues in length, and of varying
composition and charge, out of the DV and into the parasite’s cytosol. Wild-type PfCRT transports a broader range of peptides, and has a higher capacity
for peptide transport, than most CQ-resistance-conferring isoforms of PfCRT. The diminished abilities of the mutant transporters to efflux peptides results
in the accumulation of these peptides within CQ-resistant parasites. Moreover, the promiscuous degradation of the accumulated peptides leads to the
build-up of small peptide fragments and amino acids, which exerts further osmotic pressure upon the DV and causes feedback inhibition of the digestion of
host proteins. PfCRT therefore serves two roles: (1) it prevents osmotic stress of the DV by exporting peptides and (2) it delivers these peptides to the
cytosol where they are degraded into amino acids to fuel parasite growth. AAT1: amino acid transporter 1.
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(the Na+ was replaced with choline). The transport of [3H]CQ was measured as
described above.
For the data presented in Figs. 2f and 5d, the rate of CQ transport above that
measured in the relevant buffer-injected control was calculated. A least-squares fit
of the Michaelis–Menten equation (v=Vmax[substrate]/(Km+ [substrate])) was
then fitted to the data in SigmaPlot Windows Version 11.0 to derive the kinetic
parameters for the trans-stimulation of [3H]CQ transport by an unlabelled
substrate. At least four independent experiments were performed (on different days
and using oocytes from different frogs), and within each experiment measurements
were made from ten oocytes per treatment.
A total of 95 peptides derived from either haemoglobin or other erythrocytic
proteins were tested in the cis-inhibition and trans-stimulation assays. These tests
were conducted in two phases: peptides that were screened before the peptidomic
datasets were obtained and those which were selected for study on the basis of these
datasets. The first round of testing consisted of 54 peptides that were predicted by
an in silico analysis to be generated from human haemoglobin by the parasite-
encoded proteases present within the DV. The known cleavage sites of these
proteases were plotted within the α- and β-haemoglobin sequences to yield peptide
fragments that were likely to exist in the DV61–66. The second round of testing was
performed with 41 peptides that were selected from the peptidomic datasets as
candidate substrates or non-substrates of PfCRT. These experiments were
undertaken to determine if the peptidomic results could be used to predict whether
a given host-derived peptide is likely to be a substrate of PfCRT.
The characterisation of [3H]VF-6 transport via 23 different field and
laboratory-derived isoforms of PfCRT was undertaken with oocytes two days
post-cRNA-injection (Figs. 3a–j, 4; Supplementary Fig. 2). The oocytes were
injected with 25 nL of ND96 buffer (pH 5.5) supplemented with [3H]VF-6 and
unlabelled VF-6 to achieve estimated intracellular concentrations of 1.4 and
200 μM, respectively. Ten oocytes that had resealed at the injection site were
transferred to a 5 mL polystyrene round bottom tube (In Vitro Technologies)
and washed with 3.5 mL of ND96 buffer before being transferred to separate
wells of a white 96-well plate (PerkinElmer). This treatment served to establish
the amount of radioactivity within the oocytes immediately prior to the
commencement of the transport assay. Another 10 resealed oocytes were
transferred to a 5 mL tube and washed with 3.5 mL of ND96 buffer. The assay
commenced with the addition of 100 μL of ND96 buffer and the oocytes were
incubated at 27.5 °C for 1.5 h (unless specified otherwise; Fig. 3b). The assay was
terminated by removing the reaction buffer with a pipette and washing the
oocytes twice with 3.5 mL of ice-cold ND96 buffer. Each oocyte was transferred
to a separate well of a white 96-well plate. The oocytes were lysed by the
addition of 20 μL of 10% (w/v) SDS and overnight incubation at room
temperature. The lysed oocyte was then combined with 150 μL of MicroScint-40
microscintillant (PerkinElmer), the plate covered with a TopSeal-A
(PerkinElmer), and the radioactivity measured with a MicroBeta2 microplate
liquid scintillation analyser (PerkinElmer). VF-6 transport was calculated by
subtracting the amount of radioactivity (measured in counts per minute)
present within the oocytes at the end of the incubation from that measured in
the oocytes sampled immediately before the commencement of the assay. The
pH-dependence of transport (Fig. 3c) was determined by injecting the oocytes
with [3H]VF-6 suspended in 25 nL ND96 buffer adjusted to pH 5.0, 5.5, 6.0 or
7.0, which corresponded to the injection of 2.5–250 fmol of H+. The
dependence of [3H]VF-6 transport on Na+ or Cl− was examined by injecting
the oocytes with [3H]VF-6 suspended in the control ND96 buffer (pH 5.5) or a
version of this buffer that lacked either Na+ or Cl− (Supplementary Fig. 2). Na+
was replaced with 96 mM of KCl and Cl− was replaced with gluconate salts of
Na+ (NaC6H11O7; 96 mM), K+ (KC6H11O7; 2 mM), Mg2+ (MgC12H22O14;
1 mM) and Ca2+ (CaC12H22O14; 1.8 mM). The dependence of peptide transport
on Ca2+ was determined by injecting the oocytes with [3H]VF-6 suspended in
ND96 buffers that contained different concentrations of Ca2+ (0–5 mM;
Supplementary Fig. 2). The dependence of [3H]CQ transport on Na+, Cl− or
Ca2+ were conducted by suspending the oocytes in the aforementioned ND96
buffers and measuring the uptake of [3H]CQ transport into the oocyte. The
dependence of PfCRT-mediated transport on the membrane potential was
examined by using (1) Na+ ionophore III in conjunction with the Na+ gradients
listed in Supplementary Data 7 and (2) Cl− ionophore III in conjunction with
the Cl− gradients listed in Supplementary Data 7 to clamp the membrane
potential of the oocyte from −80 to +80 mV. Both the efflux of [3H]VF-6 from
the oocyte (Fig. 3d) and the influx of [3H]CQ into the oocyte (Supplementary
Fig. 2g) were measured under these conditions. Analyses of the kinetics of VF-6
transport via PfCRT (Figs. 3e and 4a) were undertaken by injecting the oocytes
with ND96 buffer pH 5.5 supplemented with [3H]VF-6 (to achieve an estimated
intracellular concentration of 1.4 μM) and unlabelled VF-6 (to achieve
estimated intracellular concentrations between 0–1150 μM). The kinetic
parameters for VF-6 transport via different isoforms of PfCRT (Figs. 3e and 4a)
were determined in SigmaPlot Windows Version 11.0 by a least-squares fit of
the Michaelis–Menten equation to the data.
A subset of assays measured the ability of solutes known to interact with PfCRT
to either cis-inhibit, trans-inhibit or trans-stimulate [3H]VF-6 transport. These
experiments involved adding these solutes to either the cis- or trans-side of the
membrane relative to [3H]VF-6. The IC50 values presented in Fig. 3h and
Supplementary Fig. 2 were determined in SigmaPlot Windows Version 11.0 by a
least-squares fit of the equation y= ymin+ [(ymax− ymin)/(1+ ([compound]/IC50)c])
to the data, where y is PfCRT-mediated VF-6 transport, ymin and ymax are the
minimum and maximum values of y and c is a fitted constant. At least five
independent experiments were performed (on different days and using oocytes from
different frogs), and within each experiment measurements were made from ten
oocytes per treatment.
Measurements of the uptake or efflux of a number of other radiolabelled
compounds (Fig. 3k; Supplementary Fig. 3) were performed using the methods
described above for [3H]CQ and [3H]VF-6, respectively.
Western blot analyses. Semiquantitative measurements of the level of PfCRT
protein in the oocyte membrane were performed using an established Western blot
protocol16 and with oocytes three days post-cRNA-injection. Briefly, the proteins
present in the oocyte membrane preparations were separated on a 4–12% NuPAGE
Bis-Tris SDS-polyacrylamide gel (ThermoFisher Scientific) and transferred to a
0.45 μM nitrocellulose blotting membrane (Amersham, GE Healthcare Life Sci-
ences). The membranes were probed with rabbit anti-PfCRT antibody (con-
centration of 1:4000; GenScript) followed by horseradish peroxidase-conjugated
goat anti-rabbit antibody (1:8000; ThermoFisher Scientific). Validation of the
specificity of the anti-PfCRT antibody has been published in detail elsewhere16.
The band for each PfCRT isoform was detected with Supersignal West Pico
Chemiluminescent reagent (Pierce), quantified using the Image J software67, and
expressed as a percentage of the intensity measured for the PfCRT3D7 band. Total
protein staining was used to evaluate sample loading and efficiency of transfer16. At
least five independent experiments were performed (using oocytes from different
frogs), and in each experiment measurements were averaged from two separate
replicates.
Immunofluorescence assays. An immunofluorescence assay was used to localise
PfCRT in oocytes three days post-cRNA-injection21. The oocytes were fixed with
4% (v/v) paraformaldehyde and permeabilised with 100% methanol. After a series
of incubations in blocking solutions, the oocytes were first incubated with the
rabbit anti-PfCRT antibody (1:100; GenScript), and then with the Alexa Fluor 488
donkey anti-rabbit antibody (1:500; ThermoFisher Scientific). The oocytes were
embedded in an acrylic resin using the Technovit 7100 plastic embedding system
(Kulzer). A microtome was used to obtain ~4 μm slices of the oocytes, which were
mounted on microscope slides. Images of the slices were obtained with a Leica Sp5
inverted confocal laser microscope (Leica Microsystems) using the ×63 objective.
Excitation was achieved with a 488 nm argon laser and the emissions were captured
using a 500–550 nm filter. Images were acquired using the Leica Application Suite
Advanced Fluorescence software (Leica Microsystems). At least two independent
experiments were performed (on oocytes from different frogs) for each oocyte type,
within which slices were examined from at least five oocytes. All of the slices taken
from oocytes expressing a PfCRT isoform displayed a fluorescent band above the
pigment layer (i.e. consistent with the localisation of PfCRT to the plasma mem-
brane) that was not present in non-PfCRT-expressing oocytes.
P. falciparum H+-efflux assays. Saponin-isolated trophozoite-stage parasites
containing the membrane-impermeant pH-sensitive fluorescent indicator
fluorescein-dextran (10,000 MW; Life Technologies) in their DVs were prepared
using a lysis-and-resealing technique that has been detailed elsewhere36,37.
Trophozoite-stage parasites were isolated with saponin and suspended in a saline
solution (125 mM NaCl, 5 mM KCl, 1 mM MgCl2, 20 mM glucose, 25 mM HEPES;
pH 7.1) at a density of 1 × 107 cells/mL. The fluorometry experiments were
performed as outlined previously37. The pH of the DV was monitored at 37 °C
using a PerkinElmer Life Sciences LS50B fluorometer with a dual excitation Fast
Filter accessory (excitation wavelengths 490 and 450 nm; emission wavelength 520
nm). The experiments entailed monitoring the alkalinisation of the DV upon the
addition of the V-type H+-ATPase inhibitor concanamycin A (100 nM; Sigma-
Aldrich), in the presence or absence of the test solutes. Half-times for the rate of
DV alkalinisation were determined in SigmaPlot Windows Version 11.0 by a least-
squares fit of the equation F= F0+ Fmax/[1+ (t/t1/2)c], where F is the fluorescence
ratio, F0 is the initial fluorescence ratio (averaged over 20 s immediately prior to
opening the chamber of the fluorometer and adding the concanamycin A), t is
time, t1/2 is the half-time for DV alkalinisation, Fmax is the maximal change in
fluorescence ratio and c is a fitted constant36. The rate of PfCRT-mediated DV
alkalinisation was calculated by subtracting the rate of DV alkalinisation of the
solvent control from that of each treatment within each parasite line (Fig. 5a–c;
Supplementary Fig. 8). In all cases, five independent experiments were performed
on different days.
P. falciparum proliferation assays. Parasite proliferation was measured in 96-well
plates using a fluorescent DNA-intercalating dye68,69. Synchronous ring-stage
parasite cultures (~1% haematocrit and 1% parasitaemia) were incubated with
different concentrations of the test compound for 72 h at 37 °C and under reduced
O2 conditions. The assay was terminated by freezing and thawing the samples, after
which 100 μL of SYBR Safe DNA Gel Stain (Molecular Probes; 0.2 μL/mL) in a lysis
buffer (20 mM Tris-HCl, 5 mM EDTA, 0.008% (w/v) saponin and 0.08% (v/v)
Triton X-100; pH 7.5) was added to each well. The fluorescence from each well was
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measured using a Tecan Infinite M1000 PRO microplate reader (excitation
wavelength 490 nm; emission wavelength 520 nm). The fluorescence values for the
wells containing the highest concentration of the compound were averaged and this
value was then subtracted from each of the well values obtained for that 96-well
plate. The level of parasite proliferation in the presence of each compound con-
centration was expressed as a percentage of the proliferation measured in the
absence of the compound. The IC50s were determined in SigmaPlot Windows
Version 11.0 by a least-squares fit of the equation y= a/[1+ ([compound]/IC50)c]
to the data, where y is the percent parasite proliferation, a is the maximum change
in the percent parasite proliferation, and c is a fitted constant. In all cases, five
independent experiments were performed (on different days), and within each
experiment measurements were averaged from three replicates.
P. falciparum peptidomic analyses. The isogenic lines C2GC03, C67G8 and C4Dd2
were maintained at the same developmental stage via sorbitol synchronisation. At
the trophozoite-stage, P. falciparum-infected erythrocytes were enriched (>95%
parasitaemia) via magnetic separation (Colebrook Bioscience) and incubated at
37 °C for 1 h prior to metabolite extraction (to ensure recovery). Two peptide
analyses were conducted, one for smaller peptides (< 8mer) and one for larger
peptides (>8 mer). Cell density was estimated by haemocytometer and 1 × 108 and
6 × 108 cells were used per sample for the small and large peptide analyses,
respectively. The cell suspension was transferred into a microcentrifuge tube
(2 mL) and metabolites/endogenous peptides were extracted using 80% (v/v)
acetonitrile or 90% (v/v) methanol for the small or large peptide analyses,
respectively70. Following centrifugation, the supernatants were collected and stored
at −80 °C until further processing commenced.
Detection and quantification of polar metabolites including endogenous small
peptides (typically < 8 mers) was performed on an Agilent 6550 Q-TOF mass
spectrometer using a binary gradient with a 1200 series HPLC system (Agilent)71.
The LC–MS/MS large peptide (>8mer) analysis was performed according to the
protocol outlined previously72. Methanol extracts (90% (v/v)) were dried under
nitrogen. The samples were resuspended in 1% (v/v) formic acid in H2O and solid-
phase extraction was performed using the Oasis TM columns. Recovered samples
were lyophilised and resuspended in 50 mM triethylammonium bicarbonate
(TEAB) to a concentration of 0.33 µg/µL, with 25 µg of peptide material per sample
used for downstream dimethyl labelling. Dimethyl labelling was performed72. A
fresh 4% (v/v) solution of light (CH2O) and medium (CD2O) formaldehyde was
prepared and the light formaldehyde was added to the C2GC03 samples and the
heavy formaldehyde was added to the corresponding C4Dd2 and C67G8 samples.
0.6 M NaBH3CN was added, incubated for 1 h (ambient) and then quenched with
1% (v/v) ammonia solution. Samples were re-acidified (100% formic acid) and
C2GC03 samples were mixed equally (but separately) to both the C4Dd2 and C67G8
samples. The three biological replicates were also reverse labelled (dimethyl heavy
for C2GC03 and dimethyl light for C4Dd2 and C67G8) and analysed to ensure
accurate quantitation between each cell line.
LC–MS/MS was carried out on a LTQ Orbitrap Elite (Thermo Scientific) with a
nanoESI interface in conjunction with an Ultimate 3000 RSLC nanoHPLC (Dionex
Ultimate 3000). The LC system was equipped with an Acclaim Pepmap nano-trap
column (Dionex-C18, 100 Å, 75 µm × 2 cm) and an Acclaim Pepmap RSLC
analytical column (Dionex-C18, 100 Å, 75 µm × 50 cm). The peptides were injected
onto the enrichment column at an isocratic flow of 5 µL/min of 3% (v/v)
acetonitrile containing 0.1% (v/v) formic acid before the enrichment column was
switched in-line with the analytical column. The eluents were 0.1% (v/v) formic
acid (solvent A) and 100% (v/v) acetonitrile in 0.1% (v/v) formic acid (solvent B).
The flow gradient was (1) 0–6 min at 3% (v/v) solvent B, (2) 6–95 min at 3–20% (v/
v) solvent B, (3) 95–105 min at 20–40% (v/v) solvent B, (4) 105–110 min at 40–80%
(v/v) solvent B, (5) 110–115 min at 80–85% (v/v) solvent B, (6) 115–117 min at
85–3% (v/v) and (7) equilibrated at 3% (v/v) solvent B for 10 min before the next
sample injection. The LTQ Orbitrap Elite spectrometer was operated in the data-
dependent mode with nanoESI spray voltage of 1.8 kV, capillary temperature of
250 °C and S-lens RF value of 55%. All spectra were acquired in positive mode with
full scan MS spectra from m/z 300–1650 in the FT mode at 240,000 resolution. The
automated gain control was set to a target value of 1.0e6 and a lock mass of
445.120025 was used. The top 20 most intense precursors were subjected to rapid
collision induced dissociation (rCID) with normalised collision energy of 30 and
activation q of 0.25. Dynamic exclusion of 30 s was applied for repeated precursors.
The small peptide data collected by LC–MS were converted into mzXML format
using MSconvert and analysed using MAVEN73. The data were aligned using a
polynomial degree of 5 and ion chromatograms were extracted using a permissive
threshold (signal/noise > 4) with a mass tolerance of 10 ppm. Peptide identification
was achieved with a pre-existing exact mass peptide library and where possible,
confirmation with MS-MS spectra matching and/or reference to authentic peptide
standards. The data are presented as the mean across 2–6 biological replicates
presented as log2 ratios.
The large peptide data were analysed using the MaxQuant (1.5.2.8) software
package using the default parameters unless specified. Peptide identification was
achieved using a custom protein library containing the top 50 proteins detected
within the sample (the most abundantly degraded proteins in the P. falciparum-
infected erythrocyte), using the unspecific digestion search mode and minimum
peptide size of five amino acid residues. Variable modifications included oxidation
and N-terminal acetylation, and no fixed modifications were permitted. Peptide
spectral matching false-discovery rate was set to 1% using the reverse decoy
database. Peptide quantification was achieved using the dimethyl lysine and
dimethyl terminal light and medium labels (0 and 4, respectively) and re-
quantification performed when only singletons were detected. The raw heavy/light
ratios (reflecting the relative peptide abundance between two cell lines) were
compared to the inverse ratios acquired from the label switch data and the average
taken between both samples. The mean of the log2 ratios across three biological
replicates was calculated and peptides only detected in one replicate were removed
from the dataset. The large peptide dataset was then merged with the small peptide
dataset and where the same peptide was detected in both datasets the LC–MS/MS
quantification was used. The data are presented as the mean across three biological
replicates presented as log2 ratios.
Statistical analysis of the peptidomic data presented in Fig. 7 and
Supplementary Data 3–5 was performed using the R package mclust74. mclust fits a
mixture model to the data using an expectation-maximisation algorithm and Bayes
Information Criteria to select the optimal number of clusters and to estimate the
mean and covariance structure for each cluster.
Quantification and statistical analyses. The statistical tests and data analyses
were performed using InStat Version 3, Image J Version 1.8.0, SigmaPlot
Windows Version 11.0, MAVEN Version 3.6, MaxQuant Version 1.5.2.8 or R
statistical software Version 3.6.3. Statistical comparisons were made using one-
way ANOVAs in conjunction with either Tukey’s multiple comparisons test or a
two-tailed one-sample t-test corrected for multiple hypothesis testing using the
Benjamini–Hochberg procedure. Unless stated otherwise, all errors cited in the
text and shown in the figures represent the standard error of the mean (SEM).
Where not shown, error bars fall within the symbols. Significance was defined as
P < 0.05. The key statistical details for each dataset are included in the figure
legends.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data supporting the findings of this study are available within the paper and
Supplementary Information. Source data are provided with this paper.
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